GeoVax entered an exclusive worldwide license agreement with Emory University granting rights to patent applications and associated know-how for combining Gedeptin with immune checkpoint inhibitors within a defined field. Financial terms were not disclosed.

The license supports GeoVax’s planned Phase 2 neoadjuvant trial in head and neck squamous cell carcinoma and preclinical assessments of additional solid tumor indications, reinforcing its move into combination-based clinical development.

GeoVax bolsters its long-standing Emory collaboration and strengthens its intellectual property position around Gedeptin-based combination therapies, positioning the company for potential partnerships and enhanced checkpoint inhibitor efficacy in earlier treatment settings.